Skip to main content

Table 2 Summary of trial design

From: Surfactant therapy for acute respiratory failure in children: a systematic review and meta-analysis

Trial Patient populationa Number of centres Surfactant
(doseb)
Control Primary outcome Duration of follow-up Funding source
Luchetti, 1998 Severe bronchiolitis Unclear, probably 1 Poractant – porcine
(50 mg/kg single dose)
None Unclear PICU discharge Not reported
Willson, 1999 ARDS/ALI 8 Calfactant – bovine
(2,800 mg/m2 every 12 hours for 1–4 doses)
None Mortality Hospital discharge Partial support by surfactant manufacturer
Tibby, 2000 RSV-induced respiratory failure Unclear, probably 1 Beractant – modified bovine
(100 mg/kg every 24 hours for 2 doses)
Air placebo Indices of gas exchange Hospital discharge Not reported
Luchetti, 2002 RSV-induced respiratory failure 6 Poractant – porcine
(50 mg/kg dose every 24 hours for 1–2 doses)
Sedation and manual ventilation Vent days and PICU stay PICU discharge Not reported
Moller, 2003 ARDS 19 Bovactant – bovine
(100 mg/kg, 1–2 doses within 48 hours)
None Change in PaO2/FiO2 at 48 hours 30 days Surfactant manufacturer
Willson, 2005 ARDS/ALI 21 Calfactant – bovine
(2,800 mg/m2 – if <10 kg, 105 mg/kg – every 12 hours for 1–2 doses)
Air placebo Ventilator-free days at day 28 Hospital discharge Surfactant manufacturer
  1. ALI, acute lung injury; ARDS, acute respiratory distress syndrome; PICU, paediatric intensive care unit; RSV, respiratory syncytial virus. aSee Additional file 1 for the complete inclusion criteria and exclusion criteria. bDose expressed as mg/kg phospholipids.